Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Abbott

Are Wall Street Analysts Predicting Abbott Laboratories Stock Will Climb or Sink?

As Abbott Laboratories has outperformed the broader market over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

‘A Goal of Ours’—U.S. Soccer Standouts Talk Growth of Game Ahead of PL Summer Series

‘A Goal of Ours’—U.S. Soccer Standouts Talk Growth of Game Ahead of PL Summer Series

Tyler Adams and Tim Howard spoke to Sports Illustrated about the growth of soccer in the U.S.

Sports Illustrated

3 Dividend Stocks With 100+ Years of History and Sky-High Growth

3 Dividend Stocks With 100+ Years of History and Sky-High Growth

These three century-old companies boast strong buy ratings, 50%+ dividend growth, and rock-solid fundamentals—ideal picks for long-term income investors.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield

Abbott Laboratories' dividend is safe, the pipeline is strong, and the outlook for growth is positive, making the July price dip a buying opportunity.

Eased Tariff Impact Fails To Lift Abbott As Outlook Cut Disappoints Investors

Abbott Laboratories (NYSE:ABT) reported better-than-expected sales and profits in the second quarter, but the stock still plummeted nearly 10% after management dialed back earnings and growth projections for the rest of the year.

Abbott Laboratories Sheds 8% On A Rare Guidance Miss

Abbott stock toppled Thursday after the health giant issued a light organic sales outlook for 2025, though it beat quarterly estimates.

Investors Business Daily

Always Sunny In Philadelphia's Gang Was Back At Their Worst In The Abbott Elementary Crossover, But Quinta Brunson Shocked Me With The Biggest Spit Take Moment

Quinta Brunson's Janine vs. Kaitlin Olson's Dee!

inkl

Read news from The Economist, FT, and more,
with one subscription

Why Diabetes Titans Dexcom, Tandem, Insulet Just Hit The Skids

Why Diabetes Titans Dexcom, Tandem, Insulet Just Hit The Skids

Shares of Dexcom, Tandem Diabetes and Insulet skidded Tuesday on a proposal that would cut Medicare reimbursements for wearable diabetes tech.

Investors Business Daily

Quinta Brunson: Abbott Elementary cast would 'love to pursue other projects'

Quinta Brunson: Abbott Elementary cast would 'love to pursue other projects'

Quinta Brunson feels "blessed" that Abbott Elementary is still popular but admitted she's looking forward to a different role in the future.

2 ‘Strong Buy’ Stocks That the MAHA Movement AND Wall Street Love

2 ‘Strong Buy’ Stocks That the MAHA Movement AND Wall Street Love

Policies associated with the MAHA movement could boost these two stocks significantly.

What to Expect From Abbott Laboratories' Q2 2025 Earnings Report

What to Expect From Abbott Laboratories' Q2 2025 Earnings Report

Abbott is poised to release its second-quarter results next month, and analysts project a single-digit earnings growth.

3 Dividend Growth Stocks To Buy and Hold Forever

3 Dividend Growth Stocks To Buy and Hold Forever

These three companies have a high 5-year dividend yield, providing long-term stability while maximizing income.

3 Dividend Aristocrats With Explosive Earnings and Bulletproof Payouts

3 Dividend Aristocrats With Explosive Earnings and Bulletproof Payouts

Discover 3 Dividend Aristocrats with high earnings growth, low payout ratios, and strong analyst ratings: perfect for long-term income investors.

Abbott Laboratories Stock: Is ABT Outperforming the Health Care Sector?

Abbott Laboratories Stock: Is ABT Outperforming the Health Care Sector?

Abbott Laboratories has outperformed the Health Care sector over the past year, and analysts are highly optimistic about the stock’s prospects.

Get all your
news in one place.

100’s of premium titles.
One news app.

The 3 Most Powerful Dividend Kings You’ve Probably Overlooked

These three Dividend Kings have strong cash flow and EPS growth, making a compelling case for long-term income investors.

Investors Business Daily

How Boston Scientific's Surprise Setback Bolstered Two Of Its Top Rivals

Edwards Lifesciences stock jumped Wednesday after Boston Scientific said it would stop selling its rival heart-valve replacement systems.

3 Oversold Dividend Aristocrats Wall Street Says Are Ready to Rally

Markets rise on improving geopolitical sentiment, leaving some quality dividend stocks to remain oversold.

Is Wall Street Bullish or Bearish on Abbott Laboratories Stock?

As Abbott Laboratories has outperformed the broader market over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

Get all your
news in one place.

100’s of premium titles.
One news app.

Wall Street’s Best-Kept Secret? These 3 Dividend Stocks Are Outperforming Big Tech

These three Dividend Kings are beating the market in 2025, offering strong yields, reliable growth, and solid analyst buy ratings.

MotoAmerica Revolutionises Rapid Concussion Testing in Sport With New Blood Test

The last time a helmet saved my life, I certainly wasn't feeling right for some time. I was dizzy, to say the least, but did I have a concussion? I don't know, and that's a problem in motorcycle racing. I continued to ride that day, but if I'd had Abbott's…

Investors Business Daily

If A Recession Hits, Will Medical Stocks Be A Safe Haven For Investors — Again?

Medical stocks could see a resurgence if the economy hits a speed bump due to tariffs. But which health care stocks are worth watching?

Sports Illustrated

2025 Boston Marathon: Sharon Lokedi Shatters Course Record in Dominant Win

Lokedi broke the course record with a time of 2:17:22.

Investors Business Daily

Stock Market Tumbles On Nvidia Export Curbs, Fed Chief Powell, UnitedHealth: Weekly Review

The stock market sold off this week, with Nvidia AI chip export curbs, UnitedHealth guidance and Fed chief Jerome Powell's comments in focus.

Tariff-Resistant Abbott Laboratories on Track for New Highs

Abbott Laboratories stock price is on track to hit a new high in 2025 and could do it before the end of the first half. Dividends and buybacks help.

Investors Business Daily

Abbott Makes A Bullish Move, Shrugging Off Covid Test Malaise

Abbott stock jumped Wednesday despite a mixed first-quarter report thanks to light sales of its Covid tests.

People

132,782 stories

Christian Pulisic

Mark Zuckerberg

Robert F. Kennedy Jr

Weston McKennie

Brandon Vazquez

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

Bank of America

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

293,968 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play